Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab versus placebo in adults with nonrelapsing secondary progressive multiple sclerosis
NL-OMON60921Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Frexalimab with Placebo (2 arms). Primary endpoint: Time to onset of composite confirmed disability progression confirmed over 6 months. Started Apr 2025; status: active, not recruiting.
02
Drugs
frexalimab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON60921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60921.